- Completed Orders: 0
- Feedback: No feedback yet
|Position - Company|
Consultant - OriGene Technologies, Inc
A gene centric life sciences tool company.
|Aug 2010 - Jan 2011|
Founder, President and CEO, and then CSO - Blue Heron Biotech, LLC.
Founded the company and served as its chief executive for the first six years. Grew the company from a technology concept to a commercial entity. Raised venture financing, participated in forming strategic alliances, managed the IP strategy (including the response to a patent infringement law suit), and participated in the sale of the company. Co-inventor on major patents, PI on SBIR grants totaling $4 million.
As CSO, led a research group focused on developing technology to reduce the cost of gene synthesis, increase throughput, reduce delivery times and assemble longer genes. The group designed and deployed integrated manufacturing automation, and built a database-controlled manufacturing system.
|Jan 1999 - Aug 2010|
Director of Genomics - Darwin Molecular
Recruited and managed a research group focused on discovering new targets for drug development using genetics and genomics. Developed a new approach to target discovery that yielded an osteoporosis drug now showing positive results in Phase II clinical trials at Amgen (AMG 785). Co-inventor on the osteoporosis target patents.
|Jan 1993 - Dec 1998|
Research Assistant Professor - Stanford University School of Medicine
Co-project leader for a human genome center focused on technology development and sequencing the yeast genome. Worked with Ron Davis and David Botstein (the center directors) to write the grants and set up the first laboratory; managed the sequencing operation jointly with one other project leader. Helped take the group from the first hires and equipment purchases through to the point three years later when it had long-term funding and an effective scientific organization. Helped initiate a technology development project that reduced oligonucleotide synthesis costs several-fold.
|Jan 1991 - Jan 1994|
Postdoctoral Fellow - Stanford University
Received a Daymon Runyan-Walter Winchell postdoctoral fellowship for work on Arabidopsis genetics in the laboratory of Ronald W. Davis. Isolated and studied disease-lesion mimic mutations. Made cDNA and genomic libraries which were widely used in the Arabidopsis field.
|Jan 1988 - Jan 1991|
Graduate student - Stanford University
Bacterial genetics in the laboratory of Dr. Sharon Long. Discovered and analyzed a network of positively acting transcription factors in the bacterium Rhizobium meliloti that regulate the early stages of the interaction between the bacteria and its plant host.
|Sep 1981 - Dec 1986|
Associate Partner - Auxin Partners LLC
Auxin Partners, LLC is a professional services and investment firm. We devise and implement commercialization programs on behalf of institutions and companies developing innovative intellectual property worldwide. Auxin creates tangible monetary value from new ideas through de-risking of technology and evangelically seeking the best possible commercialization vehicles.
Auxin operates as a consortium of seasoned technologists, analysts, business development experts and licensing professionals with the unique skills and contacts needed to monetize technical innovations.
|Sep 2011 - Present|
Founder and CEO - Glycostasis, Inc.
Developing a glucose-responsive insulin formulation
|2012 - Present|
Associate Partner - Auxin Partners LLC
Turning inventions into revenue.
|2011 - Present|
Board Member - OligoCo, Inc.
High-quality, long oligonucleotides at low cost.
|Aug 2010 - Present|
|Degree - University|
|DNA synthesis and biological security. Nat Biotechnol. 25(6):627-9. doi: 10.1038/nbt0607-627. June 2007. View on PubMed.|
|Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 68(3):577-89. February 9, 2001. View on PubMed.|
|Molecular characterization of a nonneuronal human UNC18 homolog. Genomics. 37(1):19-23. doi: 10.1006/geno.1996.0515. October 1, 1996. View on PubMed.|
|Regulation of syrM and nodD3 in Rhizobium meliloti. Genetics. 134(2):435-44. June 1993. View on PubMed.|
|Lambda YES: a multifunctional cDNA expression vector for the isolation of genes by complementation of yeast and Escherichia coli mutations. Proc Natl Acad Sci U S A. 88(5):1731-5. March 1, 1991. View on PubMed.|
|A family of activator genes regulates expression of Rhizobium meliloti nodulation genes. Genetics. 122(1):7-18. May 1989. View on PubMed.|
|Specific binding of proteins from Rhizobium meliloti cell-free extracts containing NodD to DNA sequences upstream of inducible nodulation genes. Genes Dev. 2(3):282-93. March 1988. View on PubMed.|
|Extended Region of Nodulation Genes in Rhizobium meliloti 1021. II. Nucleotide Sequence, Transcription Start Sites and Protein Products. Genetics. 117(2):191-201. October 1987. View on PubMed.|
|Expression of Rhizobium meliloti nod genes in Rhizobium and Agrobacterium backgrounds. J Bacteriol. 169(7):3094-8. July 1987. View on PubMed.|
|Transcription of Rhizobium meliloti nodulation genes. Identification of a nodD transcription initiation site in vitro and in vivo. J Biol Chem. 262(14):6849-55. May 15, 1987. View on PubMed.|
|Induction of Rhizobium meliloti nodC expression by plant exudate requires nodD. Proc Natl Acad Sci U S A. 82(19):6609-13. October 1985. View on PubMed.|
|Nucleotide sequence of Rhizobium meliloti 1021 nodulation genes: nodD is read divergently from nodABC. DNA. 4(3):241-8. doi: 10.1089/dna.1985.4.241. June 1985. View on PubMed.|
|Mutations affecting regulation of methionine biosynthetic genes isolated by use of met-lac fusions. J Bacteriol. 151(2):609-19. August 1982. View on PubMed.|